Current dilemmas in inhibiting the renin-angiotensin system: Do not forget real life

International Urology and Nephrology

Volumn 39, Issue 2, 2007, Pages 571-576

  Covic, Adrian ^a   Gusbeth Tatomir, Paul ^a   Goldsmith, David J A ^b  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

ACE inhibitors; ALLHAT trial; Angiotensin receptor antagonists; Chronic kidney disease; Diabetic nephropathy; Progression

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HUMAN ALBUMIN; LISINOPRIL; PERINDOPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MEGADOSE; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; LOW DRUG DOSE; META ANALYSIS; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMATIC REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; HUMANS; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 34447344037     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-007-9211-0     Document Type: Article

References (24)

1. Casas JP, Chua W, Loukogeorgakis S et al (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366:2026-2033
2. Suissa S, Hutchinson T, Brophy JM, Kezouh A (2006) ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 69:913-919
3. Mann JF, McClellan WM, Kunz R et al (2006) Progression of renal disease - can we forget about inhibition of the renin-angiotensin system? Nephrol Dial Transplant 21:2348-2351
4. Ritz E, Dikow R (2006) Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol 2:562-567
5. Leenen FH, Nwachuku CE, Black HR et al (2006) Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 48:374-384
6. Rossing P, Parving H-H, de Zeeuw D (2006) Renoprotection by blocking the RAS in diabetic nephropathy - fact or fiction? Nephrol Dial Transplant 21:2354-2357
7. Jafar TH, Stark PC, Schmid CH et al (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139:244-252
8. Dahlöf B, Sever PS, Poulter NR et al (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 366:895-906
9. Remuzzi G, Perico N, Macia M et al (2005) The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int 99:S57-S65
10. Bianchi S, Bigazzi R, Campese VM (2006) Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 70:2116-2123
11. Lit YZ, Meyer TW (2006) Work to do on renin-angiotensin system blockade. Clin J Am Soc Nephrol 1:611-612
12. Cryosostomou A, Pedagogos E, MacGregor L, Becker GJ (2006) Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1:256-262
13. Casas JP, Hingorani AD, MacAllister RJ, Smeeth L (2006) Progression of renal disease - can we forget about inhibition of the renin-angiotensin system? Author's reply. Nephrol Dial Transplant 21:2352-2353
14. Rahman M, Pressel S, Davis BR et al (2005) Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Arch Intern Med 165:936-946
15. Suissa S (2006) Renoprotection by blocking the RAS in diabetic nephropathy - fact or fiction? Author's reply. Nephrol Dial Transplant 21:2357-2358
16. Gilbertson DT, Liu J, Xue JL et al (2005) Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16:3736-3741
17. Foley RN, Murray AM, Li S et al (2005) Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16:489-495
18. Covic A, Haydar AA, Goldsmith DJ (2003) Recent insights from studies using ambulatory blood pressure monitoring in patients with renal disease. Curr Opin Nephrol Hypertens 12:645-648
19. Williams B, Lacy PS, Thom SM et al (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the conduit artery function evaluation (CAFE) study. Circulation 113:1213-1225
20. London GM, Marchais SJ, Guérin AP et al (2002) Impairment of arterial function in chronic renal disease: Prognostic impact and therapeutic approach. Nephrol Dial Transplant 17:13-15
21. Covic A, Mardare N, Gusbeth-Tatomir P et al (2006) Arterial wave reflections and mortality in haemodialysis patients - only relevant in elderly, cardiovascularly compromised? Nephrol Dial Transplant 21:2859-2866
22. Fournier A, Messerli FH, Achard JM et al (2004) Cerebroprotection mediated by angiotensin II: A hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 43:1343-1347
23. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709-717
24. Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543-551